NXP Semiconductors (NXPI)
(Delayed Data from NSDQ)
$282.77 USD
+2.58 (0.92%)
Updated Jul 15, 2024 04:00 PM ET
After-Market: $283.70 +0.93 (0.33%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth C Momentum C VGM
Price, Consensus and EPS Surprise
NXPI 282.77 +2.58(0.92%)
Will NXPI be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for NXPI based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NXPI
Arrow Electronics (ARW) Unveils Innovative EV Charging Solution
Top Analyst Reports for NIKE, Stryker & TJX
NXPI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why NXP Semiconductors (NXPI) Gained But Lagged the Market Today
NXP Semiconductors (NXPI) Outperforms Broader Market: What You Need to Know
NXP Semiconductors (NXPI) Boosts EV Portfolio With ZF Tie-Up
Other News for NXPI
NXP Semiconductors Announces Conference Call to Review Second Quarter 2024 Financial Results
EU says Chinese chip investments, trade wars might prompt market share loss: report
Interesting NXPI Put And Call Options For August 9th
Wells Fargo updated its Signature Picks, with Vertex Pharma and AvalonBay as adds
Top Analyst Reports For NIKE, Stryker & TJX